P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY
Thierry Facon,
Philippe Moreau,
Ivan Špicka,
Kenshi Suzuki,
Kwee Yong,
Joseph Mikhael,
Taro Fukao,
Kamlesh Bisht,
Nicole Armstrong,
Sandrine Macé,
Marie-Laure Risse,
Thomas Martin
Affiliations
Thierry Facon
1 Department of Hematology, Lille University Hospital
Philippe Moreau
2 Department of Hematology, University Hospital Hôtel-Dieu
Ivan Špicka
3 Department of Hematology, 1st Faculty of Medicine, Charles University and General Hospital
Kenshi Suzuki
4 Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center
Kwee Yong
5 Department of Haematology, University College Hospital
Joseph Mikhael
6 Translational Genomics Research Institute, City of Hope Cancer Center
Taro Fukao
7 Sanofi, Global Oncology
Kamlesh Bisht
7 Sanofi, Global Oncology
Nicole Armstrong
8 Sanofi, Global Medical Affairs
Sandrine Macé
9 Sanofi, Research and Development
Marie-Laure Risse
9 Sanofi, Research and Development
Thomas Martin
10 University of California San Francisco Medical Center
